Xenetic Biosciences Inc (XBIO) Stock Analysis

AI analysis of Xenetic Biosciences Inc (XBIO)

Sell

Xenetic Biosciences Inc is not a good buy right now due to significant recent price declines and ongoing losses. The current price is $1.87, which is 62.14% below its 52-week high of $4.94, indicating a weak performance. Additionally, the RSI is at 34.674, suggesting that the stock is oversold, but this does not guarantee a rebound. The company reported a net loss of $0.46 million in Q1 2026, which is a continuation of its negative earnings trend, and the forward P/E ratio is currently at 0, indicating no expected earnings growth. The main risk is the recent merger announcement that caused a 48.71% drop in stock price, reflecting market concerns about the future direction of the company.

Analyst Ratings (1)

Buy

1 Buy

0 Hold

0 Sell

Current: 1.87

Low

—

Average

—

High

—

HC Wainwright & Co.

Hold

—

2025-04-09

HC Wainwright & Co.

2025-04-09

Price Target

—

Hold

HC Wainwright & Co.

Hold

—

2025-03-20

HC Wainwright & Co.

2025-03-20

Price Target

—

Hold

HC Wainwright & Co.

Hold

—

2024-12-05

HC Wainwright & Co.

2024-12-05

Price Target

—

Hold

HC Wainwright & Co.

Hold

—

2024-11-22

HC Wainwright & Co.

2024-11-22

Price Target

—

Hold

HC Wainwright & Co.

Hold

—

2024-08-20

HC Wainwright & Co.

2024-08-20

Price Target

—

Hold

See All Ratings

Valuation Metrics

The current forward P/E ratio for Xenetic Biosciences Inc (XBIO) is 0.00, compared to its 5-year average forward P/E of -2.53.

Forward P/E

Overvalued

5Y Average P/E

-2.53

Current P/E

0.00

Overvalued

-0.97

Undervalued

-4.09

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.51

Current EV/EBITDA

0.75

Overvalued

1.15

Undervalued

-0.14

Forward P/S

Fair

5Y Average P/S

4.41

Current P/S

2.30

Overvalued

8.18

Undervalued

0.63

Alphio AI Price Scenarios for XBIO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%XBIO

$3.09

Scenario price

B

Base

Base · 50%XBIO

$2.99

Scenario price

B

Bear

Bear · 25%XBIO

$2.77

Scenario price

XBIO FAQ — answered by Alphio AI

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xenetic Biosciences Inc is not a good buy right now due to significant recent price declines and ongoing losses. The current price is $1.87, which is 62.14% below its 52-week high of $4.94, indicating a weak performance. Additionally, the RSI is at 34.674, suggesting that the stock is oversold, but this does not guarantee a rebound. The company reported a net loss of $0.46 million in Q1 2026, which is a continuation of its negative earnings trend, and the forward P/E ratio is currently at 0, indicating no expected earnings growth. The main risk is the recent merger announcement that caused a 48.71% drop in stock price, reflecting market concerns about the future direction of the company.

1 analysts cover XBIO: 1 rate it Buy, 0 Hold and 0 Sell.